–News Direct–
Rakovina Therapeutics President and Chief Science Officer Mads Daugaard and Dr. Art Cherkasov from the Vancouver Prostate Centre and UBC joined Steve Darling from Proactive to unveil an exciting collaboration agreement between Rakovina and Dr. Artem Cherkasov, granting exclusive access to the proprietary Deep Docking AI Platform for DNA-damage response targets.
Dr. Cherkasov, who was appointed to Rakovina's scientific advisory board in November 2023, brings unparalleled expertise to the table. The collaboration aims to leverage the cutting-edge capabilities of the Deep Docking AI Platform, powered by advanced AI algorithms, to revolutionize the discovery and development of targeted cancer drugs.
By harnessing the power of AI-driven molecular analysis, Rakovina can rapidly evaluate billions of molecular structures to identify potential candidates for targeted cancer therapy. This innovative approach enables the team to focus on DNA-damage response-related vulnerabilities, which are prevalent across various types of cancer.
The Deep Docking AI Platform plays a pivotal role in this process, facilitating the rapid screening of billions of drug candidates against validated DNA-damage response targets. Through predictive modeling, the platform can assess safety, efficacy, and pharmaceutical properties, enabling Rakovina to prioritize the most promising candidates for further validation.
With access to the Deep Docking AI Platform, Rakovina can expedite the drug discovery process, accelerating the transition from preclinical research to human clinical trials and potential pharmaceutical partnerships. By combining AI-driven molecular analysis with established R&D infrastructure, Rakovina aims to spearhead the development of innovative therapies that target critical vulnerabilities in cancer cells.
This collaboration underscores Rakovina's commitment to advancing precision medicine and delivering groundbreaking therapies to patients in need. With the support of Dr. Cherkasov and the cutting-edge capabilities of the Deep Docking AI Platform, Rakovina is poised to make significant strides in the fight against cancer, offering hope to millions of individuals affected by this devastating disease.
Contact Details
Proactive North America
Proactive North America
+1 604-688-8158
NA-editorial@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/accelerating-new-molecule-discovery-rakovina-therapeutics-ai-integration-452410836
Rakovina Therapeutics Inc
COMTEX_450233016/2655/2024-04-02T12:49:11
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Emerald Journal journalist was involved in the writing and production of this article.